anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Beginning in 2001, a phase-1 equivalent feasibility and safety evaluation of intramyocardial injection of autologous CD133+ bone marrow cells during elective CABG surgery was conducted at Rostock University. No procedure-related adverse events were observed and there was some improvement of myocardial contractility and perfusion. It was decided to proceed with a controlled efficacy testing, comparing the outcome of standard CABG surgery with that after CABG and CD133+ cell injection. The results of that study indicate that the additional cell injection yields a better left ventricular contractility than CABG alone (LVEF = 47.1±8% vs. 41.3±9% at 6 months). Although this result is encouraging, the trial had several limitations that hamper interpretation of the data. Most notably, no sham-injection of placebo material was performed in the control group, and standard 2D echocardiography served as the only measurement of global LV contractility. A more stringent efficacy testing is needed before large-scale clinical multicenter trials are justified.

Therefore, a prospective, full blinded, randomized, and placebo-controlled trial will be conducted at Deutsches Herzzentrum Berlin Berlin (DHZB), employing current state-of-the art measurement of global and regional LV contractility by cardiac MRI. The following hypothesis will be tested: "Patients who undergo CABG \& CD133+ cell injection do not have a higher LV ejection fraction than patient who undergo CABG alone, measured 6 months after the operation". A power analysis based on the previous trial results indicated that 29 patients per group need to be enrolled so as to reject the null-hypothesis with sufficient statistical power. A total of 60 patients will therefore be enrolled in the study and will be randomized to undergo either CABG surgery and injection of placebo or in conjunction with intramyocardial injection of autologous CD133+ enriched bone marrow cells. Bone marrow will be harvested one day prior to surgery and a CD133-enriched cell product (or placebo) will be prepared on-campus. The following day, bypass surgery will be performed and the study substance will be injected in the border zone of the infarcted myocardium. Random allocation will be performed in the cell production facility, so that neither the patient nor the surgeon nor any of the persons involved in follow-up examinations will know whether the cell product or placebo was administered. The primary outcome parameter (LVEF at 6 months) will be measured by cardiac MRI, and secondary outcome parameters include myocardial perfusion, exercise capacity, and quality-of-life assessment.
A method and medical device for generating transient bubbles is provided. Fluid is delivered under pressure through bubble generating means and thereby transient bubbles are generated. The bubbles are micro or nano sized. An ultrasonic source may be used to further vibrate the bubble generating means so as to adjust the size and size consistency of the bubbles. Infusion means may also be provided for infusing the bubbles in a patient. A therapeutic agent, in the form of or delivered in combination with, bubbles may be injected at the point of interest. An ultrasound pulse may additionally be provided to activate bubbles to enhance drug transport through tissues and across cell membranes. The device provides a means to locally generate transient bubbles, to facilitate acoustical activation of therapeutic agents, and the acoustic activation of bubbles infused within therapeutic agents, in order to enhance treatment efficacy.
The invention discloses a fermented composition of multiple probiotics and composite medicinal and edible fungi, and a preparation method and an application thereof. According to the invention, a composite polysaccharide extract is obtained by enzymolysis and extraction of various medicinal and edible fungi by using compound enzymes, and the extract is subjected to symbiotic fermentation by using multiple intestinal probiotics, such that a fermented composition is obtained. The invention also relates to an application of the fermented composition in preparing health-care products used for preventing and treating tumors. The medicinal and edible fungi adopted by the invention are any three or more than three selected from lucid ganoderma, agaricus blazei murill, shiitake, and flammulina velutipes. The fungi are subjected to crushing, soaking, and enzymolysis; and bifidobacterium and lactobacillus are added for fermentation. Through symbiotic fermentation with the intestinal probiotics, the molecular weight of medicinal and edible fungi composite polysaccharide is substantially reduced, tumor cell inhibiting activity is substantially improved, and inhibition effect is substantially improved.
PURPOSE:The titled preparation that contains a quinoxaline derivative as an active ingredient to control the inflow and outflow of the anticancer agent through the cell membrane, thus increasing the anticancer activity. CONSTITUTION:The objective preparation contains 1-(2-dialkylaminoalkyl)-3-(p- alkoxybenzyl)-1,2-dihydroquinoxalin-2-one or its salt as an active ingredient. Especially, the compound that has ethyls as the two alkyls and methoxy as the alkoxy is most preferred among these quinoxaline compounds. The anticancer agent develops its effect, when it is transferred through the cell membranes into the cells. Further, cancer cells become resistant, mostly because the accumuation and activity of the anticancer agent become low inside the cancer cells, but the quinoxaline derivatives inhibit the anticancer agent from flowing out of the cells to keep the high concentration of the agent inside the cells. Resultingly, the does of the anticancer agent can be reduced and the troubles are overcome in resistance to anticancer agents.
Lipid energy is transported in the blood in several forms, including chylomicrons and free fatty acids (FFA). Chylomicrons are key elements in the absorption and storage of dietary fat, and also play a role in the pathogenesis of atherosclerosis via the production of remnant particles, but their role as a direct fuel source has not been explored. FFA are the major lipid fuel in the body, and increases in their concentration have been shown to cause insulin resistance, endothelial dysfunction and increases in the production of very low density lipoproteins. FFA are released into the blood through the action of hormone sensitive lipase on triglyceride stores in fat cells. Very little is known about the role of chylomicrons in FFA metabolism, but the potential contribution of chylomicrons to FFA is considerable, especially in people who consume high fat diets. Initial studies indicate that in addition to the role of chylomicrons in fat storage, a portion of chylomicron fatty acids are released as FFA in a process called "spillover". These studies indicate that the contribution of chylomicrons to FFA is increased in type 2 diabetes. A study of spillover in the splanchnic bed found very high rates of splanchnic spillover in overweight and obese individuals with hypertriglyceridemia. Extremely accurate and precise methods have been developed by the investigator for the measurement of the concentration and specific activity of FFA and chylomicron triglyceride fatty acids in plasma. In addition, a tracer method for accurately determining the kinetics of chylomicrons has been developed. In the proposed studies, the tracer technique will be used to systematically investigate the contribution of chylomicrons to total FFA availability. The technique will be applied to normal subjects at rest and after exercise, as well as subjects with type 2 diabetes mellitus and hypertriglyceridemia. Specifically, these studies will: 1) determine whether weight loss in people with type 2 diabetes reduces spillover from chylomicrons; 2) determine whether acute lowering of FFA with insulin infusion reduces spillover in nondiabetic individuals with dyslipidemia; 3) determine whether noninsulin-mediated lowering of FFA reduces spillover in diabetic individuals with dyslipidemia, and 4) determine whether obese, insulin-resistant individuals have increased spillover in the splanchnic bed.
Combined with AI calculation of malignant probability and ctDNA methylation results, patients were divided into three groups. The high probability of malignancy calculated by AI was defined as positive, and vice versa. The methylation markers detected in specific peripheral blood of lung cancer were defined as positive, and vice versa. Negative for both items was considered as low risk group. Follow-up was conducted according to The Chinese Expert Consensus on the Diagnosis and Treatment of Pulmonary Nodules (2018 edition). 10ml peripheral blood was collected from each follow-up and stored for testing until the end of the study.
Part 1 is a dose finding phase in which subjects will be initially administered 75 milligram (mg) of palbociclib (21 days on/7 days off) and 1.5 mg of trametinib (once daily continuous dosing) in each 28-day cycle. Dose escalations will continue based on predefined parameters until the RCR is identified. The RCR will not exceed the maximum tolerated dose (MTD).
For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
Background \& aim Endoscopic ultrasound guided fine needle biopsy (EUS-FNB) is the main tool for tissue acquisition and pathological diagnosis of pancreatic solid mass because of its superior accuracy and lower complication rate compared to CT-guided biopsy. However, the tissue adequacy and diagnostic yield remained unsatisfactory for 2 reasons. First, the conventional dry suction technique (DST) often get small tissue and 3 or more needle passes (i.e. biopsies) are required to obtain enough specimen. Second, blood contamination of the acquired tissue interfered with microscopic examination. Investigator aim to develop a novel technique to improve tissue acquisition within a fewer needle passes and avoid blood contamination by using heparin-based modified wet suction (H-MWST).

Methods This study will be a randomized crossover clinical trial. Patients with pancreatic solid mass indicated for EUS FNB will be enrolled. EUS FNB will be done by one experienced endoscopists in National Cheng Kung University Hospital. Patients will be randomized in a 1:1 ratio to receive EUS FNB with either dry suction technique (DST) or H-MWST first for the initial 2 needle passes, and then crossover to another suction technique for a total of 4 needle passes. The obtained tissue of each needle pass will be sent separately and examined by a pathologist who is unaware of the procedure order. Procedure related complications will be recorded. The primary outcome will be the acquired tissue quality quantified comparison. The secondary outcome will be the overall diagnostic yield, the specimen adequacy, and complication rate by each suction technique.
Traditional Chinese medicine (TCM) possesses the potential of providing good curative effects with no side effects for the effective management of slow transit constipation (STC), an intestinal disease characterized by colonic dyskinesia. Mulberry leaves (Morus alba L.) and black sesame (Sesamum indicum L.), referred to as SH, are processed and conditioned as per standardized protocols. SH has applications as food and medicine. Accordingly, we investigated the therapeutic potential of SH in alleviating STC. The analysis of SH composition identified a total of 504 compounds. The intervention with SH significantly improved intestinal motility, reduced the time for the first black stool, increased antioxidant activity, and enhanced water content, thereby effectively alleviating colon damage caused by STC. Transcriptome analysis revealed the SH in the treatment of STC related to SOD1, MUC2, and AQP1. The analysis of 16S rRNA gene sequences indicated notable differences in the abundance of 10 bacteria between the SH and model. Metabolomic analysis further revealed that SH supplementation increased the levels of nine metabolites associated with STC. Integrative analysis revealed that SH modulated amino acid metabolism, balanced intestinal flora, and targeted key genes (i.e., SOD1, MUC2, AQP1) to exert its effects. SH also inhibited the AQP1 expression and promoted SOD1 and MUC2 expression.
The total individual ATG dose was calculated based on population pharmacokinetic modeling. ATG was intravenously infused every day from day -5 to day -2.
Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 444 patients, including 310 individuals (69.8%) with diagnosis of diabetic nephropathy.
Aim: To compare biomarkers and mediators associated with arterial and venous thrombosis from blood sampling from the LA, RA, and systemic circulation in patients with AF.

Methods and population: A prospective trial of patients who undergo circumferential ablation of the pulmonary veins. For the clinical procedure, a conventional transeptal puncture is performed. In the beginning of the procedure, following transeptal puncture, and before intravenous administration of unfractionated heparin (bolus of 50-100 IU/kg), blood samples will simultaneously be collected from the peripheral femoral venous sheath, arterial line, right atrial sheath, and LA sheath. Samples from the RA and LA will be collected with the sheath positioned in the midchamber and close to the appendages. Each Patient will provide up to 40ml of blood for the following blood tests: (1) Blood count. (2) Fibrinogen (3) Factor VIII (4) D-dimer (5) P-selectin (6) von Willebrand factor (7) TEG - Thromboelastography Serum and plasma samples will be stored for future tests.
The resolution of inflammation is an active process leading to the restoration of tissue homeostasis. A critical step in the initiation of this process is the elimination of apoptotic immune cells by macrophages. This well-organized process, called efferocytosis, involves four different steps, namely the attraction of macrophages to the site where the cells die, the recognition of apoptotic cells, their internalization and their digestion leading to the activation of different metabolic pathways. All these steps are responsible for the reprogramming of macrophages towards a pro-resolving profile. Efferocytic macrophages produce several factors involved in the resolution of inflammation. These factors include lipids (i.e., specialized pro-resolving mediators such as lipoxins), and proteins (e.g., IL-10 or TGF-β). Here, we describe the different steps of efferocytosis and the mechanisms responsible for both macrophage reprogramming and the release of pro-resolving factors. These factors may represent a new therapeutic approach, called resolution therapy.
Podocytes serve as part of the renal filtration unit with slit diaphragms. Although the structure of slit diaphragms between two cells is well characterized, how the tricellular contact of podocytes is organized and how it changes in injured podocytes remains unknown. This study focused on a tricellular junction protein, angulin-3, and its localization in healthy podocytes, in developmental stages, and in pathologic conditions, using a newly established monoclonal antibody. Angulin-3 was confined at tricellular junctions of primordial podocytes, then transiently localized at bicellular junctions as foot process interdigitation developed and the intercellular junctions rearranged into slit diaphragm, and eventually distributed in a sparse punctate pattern on the foot processes of adult podocytes. In the rodent podocyte injury models, angulin-3 showed bicellular localization between the foot processes, and the localization turned from punctate to dashed linear pattern along the effaced foot processes with the progression of podocyte injury. Angulin-3 also accumulated between foot processes in a linear pattern in kidney biopsy samples of human nephrotic syndrome. Additionally, the line length of angulin-3 staining signal correlated with risk of relapse under glucocorticoid therapy in patients with minimal change nephrotic syndrome. This study proposes an image program to score the linearity of the accumulation pattern of angulin-3 to evaluate the relapse risk of patients with minimal change nephrotic syndrome.
A repeat prescription ordering system for allowing patients requiring resupply of medication or medical products to access a server using a portable communications and data processing device such as a smart phone or personal digital assistant. The server supplies to the patient a list of medication and medical products which they are authorized to order. The patient can select the products required, and the order is logged by the server and allocated to a supplier for completion of the order. The server maintains an estimate of the amount of medication or medical product held by the patient, this being based on the prescribed dosage regimen and information entered by the patient on their usage and, optionally, on checks on their own health. The patient may be alerted when the estimate indicates that their supplies are running low. The estimate is allowed to go below zero, this implying a possible departure from the prescribed medication regimen.
PURPOSE:To obtain a hypoglycemic agent useful in prevention and treatment for diabetes and being safe even if taking the agent for a long period by including an extract from lactic acid bacterium cell with water as an active ingreadient. CONSTITUTION:This hypoglycemic contains an extract of lactic acid bacterium cell of Lactobacillus casei with water as an active ingreadient. The extract solution can directly be used as a medicine or can be prepared into tablet, granule, powdery preparation, capsule, injection, drop, etc., by concentrating and drying the extract solution. This extract solution can daily be taken-in by adding to food or drink. Since the lactic acid bacterium is a safe microorganism utilized in lactic acid fermented food from old time and free from pathogenicity, the hypoglycemic agent obtained by only extracting the bacterium with water has no problem even in aspect of safety. The extract having blood glucose level lowering action is obtained by culturing lactic acid bacterium by an ordinary method, separating the cultured cells by centrifugal separation, etc., and washing and extracting the cells with water, or suspending the bacterial cells in water, heating the cells at 95-100 deg.C and removing insoluble matter by centrifugation.
Children worldwide are at risk of experiencing psychological trauma. In addition, one in every four children experiences major traumatic events such as domestic, school, or social violence, abuse, vehicle accidents, serious medical diseases, terrorist incidents, and war. These difficult experiences increase the incidence of post-traumatic stress disorder in children. It is reported that approximately 30% of children who have been exposed to trauma develop post-traumatic stress disorder. Although it is sometimes difficult to diagnose post-traumatic stress disorder, it is important to detect symptoms of PTSD in children and adolescents early. Many internalizing and externalizing symptoms occur in PTSD; There may be separation anxiety, shame, guilt, low tolerance, overstimulation, impulsivity, outbursts of anger, hostility, defiance, aggression, irritability, and mood changes. Therefore, early evaluation of trauma experience and post-traumatic symptoms in children and adolescents seems important.
PROBLEM TO BE SOLVED: To prepare a remarkable health food suitable for ensuring quiet sleep and sound sleep by using composite galenicals as main raw materials in order to suppress factors disturbing the sleeps as much as possible. SOLUTION: This health food for quiet sleep contains the mixture of a Panax ginseng extract, a Ginkyo biloba extract, a Formes japonicus extract, calcium, a Rehmannia glutinosa stem extract, an Eucommia ulmodes leaf extract, a Zizyphus vulgaris extract, a Glycyrhiza glabra extract, a Citrus unshiu extract, a Chrysanthemum morfolium extract and a Coix lacrma-jobi extract in a prescribed ratio as an active ingredient.  For example, 1 pt.wt. of the Panax ginseng extract, 0.1-1.0 pt.wt. of the Ginkyo biloba extract, 0.1-0.5 pt.wt. of the Formes japonicus extract, 0.1-1.0 pt.wt. of the calcium, 0.5-3.0 pts.wt. of the Rehmannia glutinosa stem extract, 0.25-75 pt.wt. of the Eucommia ulmoides leaf extract, 1.5-3.5 pts.wt. of the Zizyphus vulgaris extract, 0.25-1.0 pt.wt. of the Glycyrrhiza glabra extract, 0.1-0.5 pt.wt. of the Citrus unshiu extract, 0.1-0.5 pt.wt. of the Chyrisanthemum morifolium extract and 0.3-2.5 pts.wt. of the Coix lacrma-jobi extract are mixed.
The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
Includes one pediatric stratum (6-11 years old). Subjects 6 to 11 years of age or subjects who weigh 40 kg, will receive a loading dose of 40 mg/kg (maximum of 1680 mg) followed by a maintenance dose of 20 mg/kg (maximum of 840 mg).
Depression:For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident.

Childhood Enuresis: May be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. In patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. The effectiveness of treatment may decrease with continued drug administration.
PROBLEM TO BE SOLVED: To provide an easily producible sugar-coated tablet finished to an elliptic form having smooth surface by forming a sugar-coating layer containing a specific binder, a filler composed mainly of fine talc powder and a sugar. SOLUTION: The sugar-coating layer of the tablet contains (A) 1-4 pts.wt. of a hydroxypropyl methyl cellulose having a hydroxypropoxyl group content of 4-12%, a methoxyl group content of 19-24% and a viscosity of <=10cP in the form of 2wt.% aqueous solution at 20 deg.C, (B) 5-25 pts.wt. of a filler composed mainly of a fine talc powder having an average particle diameter of <=5μm and (C) a sugar (preferably sucrose). The sugar-coated tablet can be produced by preparing a sugar-coating liquid containing 100 pts.wt. of a syrup liquid consisting of a mixture of the component C and water, 1-4 pts.wt. of the component A and 5-25 pts.wt. of the component B, repeating the step to apply the sugar-coating liquid to a tablet and dry the applied liquid to form a sugar- coating layer, reshaping the coated tablet to elliptic form and coating with a wax.  When the component C is sucrose and its concentration is adjusted to 60-70wt.% based on the sum of sucrose and water.
Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SEF95 obtained by SedLine® monitor to keep a SAS 1-2. The target of SEF95 will be 10-13 Hz to keep SAS 1-2.